Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 300 µg/ml;  ; timolol maleate 5 mg/ml;   - eye drops, solution - 300mcg/ml & 5mg/ml - active: bimatoprost 300 µg/ml   timolol maleate 5 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg - modified release tablet - 15 mg - active: upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry purple 85f100091 tartaric acid - rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis. rinvoq may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease modifying anti-rheumatic drugs (csdmards).

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg - modified release tablet - 30 mg - active: upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry red 85f150093 tartaric acid - rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg - modified release tablet - 45 mg - active: upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 85f120063 tartaric acid - rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - ketorolac trometamol 5 mg/ml;  ;   - eye drops, solution - 0.5% w/v - active: ketorolac trometamol 5 mg/ml     excipient: benzalkonium chloride disodium edetate dihydrate hydrochloric acid macrogols purified water sodium chloride sodium hydroxide

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - fluorometholone 1 mg/ml;   - eye drops, solution - 0.1% w/v - active: fluorometholone 1 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 polyvinyl alcohol purified water sodium chloride sodium edetate sodium hydroxide

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - gentamicin sulfate 0.3%{relative} (10% overage added) - eye drops, solution - 0.3% w/w - active: gentamicin sulfate 0.3%{relative} (10% overage added) excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate disodium edetate dihydrate hydrochloric acid polyvinyl alcohol sodium chloride sodium hydroxide water for injection - the product is indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. such infections include conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis and dacryocystitis.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 90 mg/ml;   - solution for injection - 75 mg/0.83ml - active: risankizumab 90 mg/ml   excipient: polysorbate 20 sodium succinate sorbitol succinic acid water for injection - psoriasis: skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).